Prof. Geoffrey Liu, Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
Host:Prof. Ming Gao, The First Affiliated Hospital of Zhengzhou University, China
Prof. Liu discussed the ongoing challenge of CNS progression in ALK-positive NSCLC, including how to optimize systemic TKI therapy plus local intervention and how to interpret the long-term value of first-line lorlatinib. He also shared his perspectives on treatment sequencing, patient preferences, and future directions in ALK research.